AI Article Synopsis
- Trastuzumab emtansine and trastuzumab deruxtecan are common treatments for breast cancer but can cause thrombocytopenia, leading to treatment delays or dose reductions.
- A case series of 6 breast cancer patients showed that their therapy was interrupted due to thrombocytopenia from these treatments.
- After receiving thrombopoietin receptor agonists (TPO-RA), all 6 patients were able to continue their cancer treatment effectively.
Article Abstract
Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485295 | PMC |
| http://dx.doi.org/10.1093/oncolo/oyad185 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!